Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax

Ocugen, Inc.

Multiple earnings reports and regulatory updates shook up the coronavirus vaccine space this week.

Here's Why Shares of Moderna, Novavax, and Ocugen Have All Been Extremely Volatile This Week

Moderna Inc (NASDAQ: MRNA) shares are trading lower following positive data from Pfizer for its COVID-19 oral antiviral treatment candidate. According to Pfizer: PAXLOVID™ was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with COVID-19

Why Moderna Shares Are Falling

Moderna's boosters in Europe won't have the restrictions imposed in the U.S.

Why Boosters Approval in Europe Is a Big Deal for Moderna

Moderna's future prospects are more important than one disappointing quarter.

The Only 3 Things in Moderna's Q3 Update That Really Matter

Moderna slashed the 2021 sales forecast for its COVID-19 vaccine by as much as $5 billion, grappling to fill vials and distribute them to meet unprecedented world demand.

Moderna shares plunge amid struggle to fill COVID-19 vaccine orders

It appears that Pfizer has taken the lead in the tug of war for market share among the leading COVID-19 vaccine makers, and Moderna's investors aren't happy about it.

Moderna's COVID-19 vaccine sales in the third quarter disappoint investors, and its stock takes a hit

Moderna Inc (NASDAQ: MRNA) shares are trading lower Thursday after the company announced its COVID-19 sales came in short of Wall Street analysts estimates by more than $1 billion. The company reported $5 billion in revenue for the third quarter of the year, missing the analyst estimate calling for $6.2 billion.

Moderna Cracks Below Support, Is A Recovery In Sight?

Moderna Inc (NASDAQ: MRNA) has quietly announced the discontinuation of an mRNA program for the chikungunya virus. The Company is scrapping Phase 2 plans for mRNA-1944, the antibody directed at the chikungunya virus.

Moderna Scraps mRNA-Based Antibody Program Targeting Chikungunya Virus

Moderna's (MRNA) COVID-19 vaccine sales miss expectations. The company delivers 208 million doses of its COVID-19 vaccine during the third quarter.

Moderna (MRNA) Q3 Earnings Miss, COVID-19 Vaccine Brings $5B

Moderna now anticipates full-year production between 700 million and 800 million doses, a downgrade from the previous range.

Moderna tumbles 17% after cutting 2021 vaccine-sales forecast and badly missing earnings

Due to the delays and prioritization of low-income countries, Moderna anticipates fiscal year 2021 product sales between $15B and $18B, down from previous guidance of $20 billion.

Moderna stock tanks on COVID vaccine delivery slowdown

Shares of Moderna Inc (NASDAQ: MRNA) opened more than 15% down on Thursday as sales of its COVID-19 vaccine missed estimates in the fiscal third quarter. The biotech company was also dovish on sales of its vaccine moving forward.

What made Moderna shares slip 15% on Thursday morning?

Now trading at their lowest level in three months, Moderna shares have struggled as experts question the long-term viability of the firm's Covid-19 vaccine sales.

Moderna Crash Wipes Out Another $24 Billion After Supply Chain Issues Dent Covid Vaccine Sales

Moderna (MRNA) delivered earnings and revenue surprises of -14.06% and -17.81%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Moderna (MRNA) Misses Q3 Earnings and Revenue Estimates

Moderna Inc was expected to see US$20bn wiped of its value when US markets open this afternoon after it cut its forecast for sales of its pioneering COVID-19 vaccine. The US pharma reduced its 2021 sales forecast for the vaccine by up US$5bn due to problems ramping up production.

Moderna tumbles after cut to Covid-19 vaccine sales forecast

Moderna's (MRNA) Q3 earnings and revenue came in well below analysts' consensus estimates.

Moderna Q3 2021 Earnings Report Recap

Amplify Travel Tech ETF

Global X Autonomous & Electric Vehicles ETF

Merck

SPDR S&P 600 Small Cap ETF

SPDR S&P Oil & Gas Exploration & Production ETF

SPDR S&P Retail ETF

November kicked off on a solid note after a solid October rally. Better-than-expected corporate earnings boosted the U.S. stocks.

5 ETFs Strategies to Play in November

Moderna fell short of profit and sales expectations for the third quarter, and the Covid vaccine maker warned that its full year shipments of the vaccine will not meet its forecasts.

Moderna warns its Covid vaccine shipments are falling short. Stock plunges

Moderna Inc (NASDAQ: MRNA) reports a Q3 EPS of $7.70, a turnaround from an EPS loss of $(0.59) a year ago, though missing the consensus estimate of $9.09. The Company clocked Q2 revenues of $4.96 billion compared to just $157 million a year ago, missing the consensus of $6.23 billion.

Why Are Moderna Shares Plunging Today?

Moderna shares fell Thursday after it cut its Covid-19 vaccine sales forecast for the year.

Moderna shares fall after company cuts 2021 forecast for Covid vaccine sales

Moderna Inc on Thursday cut its full-year sales forecast for its COVID-19 vaccine to between $15 billion and $18 billion from $20 billion previously, as the vaccine maker struggles with the production of its two-dose inoculation.

Moderna cuts full-year forecast for COVID-19 vaccine sales

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Reports Third Quarter Fiscal Year 2021 Financial Results and Provides Business Updates

Moderna Reports Third Quarter Fiscal Year 2021 Financial Results and Provides Business Updates

Shares of Moderna Inc. MRNA, -0.78% tumbled 9.9% in premarket trading on Thursday after the company missed on sales of its COVID-19 vaccine in the third quarter of this year. Moderna had earnings of $3.3 billion, or $7.70 per share, in the third quarter of 2021.

Moderna's shares are down 10% after COVID-19 vaccine revenue comes in lower than expected

Moderna earnings come in far short of estimates

Moderna's data showed solid production of antibodies in younger children receiving its COVID-19 vaccine.

News for Moderna Stock (MRNA)